Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy

Clinical Biochemistry

Volumn 45, Issue 15, 2012, Pages 1132-1144

  Lubamba, Bob ^a   Dhooghe, Barbara ^a   Noel, Sabrina ^a   Leal, Teresinha ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

CFTR; CFTR pathophysiology; CFTR pharmacotherapy; Chloride transport; Cystic fibrosis

Indexed keywords

ATALUREN; CHLORIDE CHANNEL; CURCUMIN; DENUFOSOL; GENISTEIN; GENTAMICIN; INO 4995; IVACAFTOR; KM 11060; LANCOVUTIDE; LUBIPROSTONE; LUMACAFTOR; MIGLUSTAT; PHLOXINE; PHOSPHODIESTERASE V; SILDENAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VARDENAFIL; VRT 325;

CHLORIDE TRANSPORT; CLINICAL FEATURE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; LUNG DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SODIUM TRANSPORT;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84866295520     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.05.034     Document Type: Review

References (202)

1. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
2. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
3. Lebecque P., Leonard A., De Boeck K., De Baets F., Malfroot A., Casimir G., et al. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. J. Cyst. Fibros. 2009, 8:26-30.
4. Anderson D.H. Cystic fibrosis of the pancreas ans its relation to celiac disease: a clinical and pathological study. Am. J. Dis. Child. 1938, 56:344-399.
5. Cystic Fibrosis Foundation Patient registry 2008, Bethesda, Maryland.
6. Gibson L.E., Cooke R.E. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959, 23:545-549.
7. Quinton P.M., Bijman J. Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis. N. Engl. J. Med. 1983, 308:1185-1189.
8. Knowles M., Gatzy J., Boucher R. Increased bioelectrical potential difference across respiratory epithelia in cystic fibrosis. N. Engl. J. Med. 1981, 305:1489-1495.
9. Tsui L.C., Buchwald M., Barker D., Braman J.C., Knowlton R., Schumm J.W., et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985, 230:1054-1057.
10. Wainwright B.J., Scambler P.J., Schmidtke J., Watson E.A., Law H.Y., Farrall M., et al. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature 1985, 318:384-385.
11. Ford R.C., Birtley J., Rosenberg M.F., Zhang L. CFTR three-dimensional structure. Methods Mol. Biol. 2011, 741:329-346.
12. Gadsby D.C., Vergani P., Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006, 440:477-483.
13. Lewis H.A., Buchanan S.G., Burley S.K., Conners K., Dickey M., Dorwart M., et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 2004, 23:282-293.
14. Linsdell P. Mechanism of chloride permeation in the cystic fibrosis transmembrane conductance regulator chloride channel. Exp. Physiol. 2006, 91:123-129.
15. Wang W., El Hiani Y., Linsdell P. Alignment of transmembrane regions in the cystic fibrosis transmembrane conductance regulator chloride channel pore. J. Gen. Physiol. 2011, 138:165-178.
16. Chen T.Y., Hwang T.C. CLC-0 and CFTR: chloride channels evolved from transporters. Physiol. Rev. 2008, 88:351-387.
17. - channel by ATP-driven nucleotide-binding domain dimerisation. J. Physiol. 2009, 587:2151-2161.
18. Vergani P., Lockless S.W., Nairn A.C., Gadsby D.C. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 2005, 433:876-880.
19. Serohijos A.W., Hegedus T., Aleksandrov A.A., He L., Cui L., Dokholyan N.V., et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3256-3261.
20. Gregory R.J., Cheng S.H., Rich D.P., Marshall J., Paul S., Hehir K., et al. Expression and characterization of the cystic fibrosis transmembrane conductance regulator. Nature 1990, 347:382-386.
21. Denning G.M., Ostedgaard L.S., Cheng S.H., Smith A.E., Welsh M.J. Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. J. Clin. Invest. 1992, 89:339-349.
22. - channel resembles the cystic fibrosis transmembrane conductance regulator. Nature 1992, 360:81-84.
23. Hume J.R., Duan D., Collier M.L., Yamazaki J., Horowitz B. Anion transport in heart. Physiol. Rev. 2000, 80:31-81.
24. - transport of mouse aortic smooth muscle cells. J. Physiol. 2005, 568:483-495.
25. Michoud M.C., Robert R., Hassan M., Moynihan B., Haston C., Govindaraju V., et al. Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 2009, 40:217-222.
26. Lamhonwah A.M., Bear C.E., Huan L.J., Kim Chiaw P., Ackerley C.A., Tein I. Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise. Ann. Neurol. 2010, 67:802-808.
27. Sprague R.S., Ellsworth M.L., Stephenson A.H., Kleinhenz M.E., Lonigro A.J. Deformation-induced ATP release from red blood cells requires CFTR activity. Am. J. Physiol. 1998, 275:H1726-H1732.
28. Decherf G., Bouyer G., Egee S., Thomas S.L. Chloride channels in normal and cystic fibrosis human erythrocyte membrane. Blood Cells Mol. Dis. 2007, 39:24-34.
29. Di A., Brown M.E., Deriy L.V., Li C.Y., Szeto F.L., Chen Y.M., et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat. Cell Biol. 2006, 8:933-952.
30. Li M.S., Holstead R.G., Wang W., Linsdell P. Regulation of CFTR chloride channel macroscopic conductance by extracellular bicarbonate. Am. J. Physiol. Cell Physiol. 2011, 300:C65-C74.
31. Garcia M.A., Yang N., Quinton P.M. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J. Clin. Invest. 2009, 119:2613-2622.
32. Ishiguro H., Steward M.C., Naruse S., Ko S.B., Goto H., Case R.M., et al. CFTR functions as a bicarbonate channel in pancreatic duct cells. J. Gen. Physiol. 2009, 133:315-326.
33. Tang L., Fatehi M., Linsdell P. Mechanism of direct bicarbonate transport by the CFTR anion channel. J. Cyst. Fibros. 2009, 8:115-121.
34. Anderson M.P., Rich D.P., Gregory R.J., Smith A.E., Welsh M.J. Generation of cAMP-activated chloride currents by expression of CFTR. Science 1991, 251:679-682.
35. Kartner N., Hanrahan J.W., Jensen T.J., Naismith A.L., Sun S.Z., Ackerley C.A., et al. Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 1991, 64:681-691.
36. Bijman J., Dalemans W., Kansen M., Keulemans J., Verbeek E., Hoogeveen A., et al. Low-conductance chloride channels in IEC-6 and CF nasal cells expressing CFTR. Am. J. Physiol. 1993, 264:L229-L235.
37. Bear C.E., Li C.H., Kartner N., Bridges R.J., Jensen T.J., Ramjeesingh M., et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992, 68:809-818.
38. Cheng S.H., Rich D.P., Marshall J., Gregory R.J., Welsh M.J., Smith A.E. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 1991, 66:1027-1036.
39. Gadsby D.C., Nairn A.C. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol. Rev. 1999, 79:S77-S107.
40. Anderson M.P., Gregory R.J., Thompson S., Souza D.W., Paul S., Mulligan R.C., et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991, 253:202-205.
41. Sheppard D.N., Welsh M.J. Structure and function of the CFTR chloride channel. Physiol. Rev. 1999, 79:S23-S45.
42. Dawson D.C., Smith S.S., Mansoura M.K. CFTR: mechanism of anion conduction. Physiol. Rev. 1999, 79:S47-S75.
43. Quinton P.M. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008, 372:415-417.
44. Markert T., Vaandrager A.B., Gambaryan S., Pöhler D., Häusler C., Walter U., et al. Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine. Implications for cystic fibrosis transmembrane conductance regulator. J. Clin. Invest. 1995, 96:822-830.
45. Stutts M.J., Rossier B.C., Boucher R.C. Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J. Biol. Chem. 1997, 272:14037-14040.
46. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 2004, 10:487-493.
47. Zhou Z., Treis D., Schubert S.C., Harm M., Schattemy J., Hirtz S., et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in bENaC-overexpressing mice. Am. J. Respir. Crit. Care Med. 2008, 178:1245-1256.
48. Jovov B., Ismailov I.I., Berdiev B.K., Fuller C.M., Sorscher E.J., Dedman J.R., et al. Interaction between cystic fibrosis transmembrane conductance regulator and outwardly rectified chloride channels. J. Biol. Chem. 1995, 270:29194-29200.
49. Stutts M.J., Canessa C.M., Olsen J.C., Hamrick M., Cohn J.A., Rossier B.C., et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995, 269:847-850.
50. + conductance when coexpressed in Xenopus oocytes. FEBS Lett. 1996, 381:47-52.
51. + conductance. Pflugers Arch. 1996, 432:516-522.
52. + channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamide is enhanced by coexpression with the ATP-binding cassette transporter cystic fibrosis transmembrane regulator. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8083-8088.
53. + channels. Kidney Blood Press. Res. 1997, 20:151-153.
54. Schreiber R., Greger R., Nitschke R., Kunzelmann K. Cystic fibrosis transmembrane conductance regulator activates water conductance in Xenopus oocytes. Pflugers Arch. 1997, 434:841-847.
55. - secretion induced by C-type natriuretic peptide (CNP). Experiments on isolated in vitro perfused rectal gland tubules of Squalus acanthias. Pflugers Arch. 1999, 438:15-22.
56. - channels. Pflugers Arch. 2001, 442:280-285.
57. Kunzelmann K. CFTR: interacting with everything?. News Physiol. Sci. 2001, 16:167-170.
58. Lukacs G.L., Chang X.B., Kartner N., Rotstein O.D., Riordan J.R., Grinstein S. The cystic fibrosis transmembrane regulator is present and functional in endosomes. Role as a determinant of endosomal pH. J. Biol. Chem. 1992, 267:14568-14572.
59. Barasch J., Kiss B., Prince A., Saiman L., Gruenert D., Al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991, 352:70-73.
60. Jouret F., Bernard A., Hermans C., Dom G., Terryn S., Leal T., et al. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J. Am. Soc. Nephrol. 2007, 18:707-718.
61. Raggi C., Fujiwara K., Leal T., Jouret F., Devuyst O., Terryn S. Decreased renal accumulation of aminoglycoside reflects defective receptor-mediated endocytosis in cystic fibrosis and Dent's disease. Pflugers Arch. 2011, 462:851-860.
62. Howard M., Jilling T., DuVall M., Frizzell R.A. cAMP-regulated trafficking of epitope-tagged CFTR. Kidney Int. 1996, 49:1642-1648.
63. Vandivier R.W., Richens T.R., Horstmann S.A., deCathelineau A.M., Ghosh M., Reynolds S.D., et al. Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297:L677-L686.
64. The Cystic Fibrosis Genetic Analysis Consortium Worldwide survey of the delta F508 mutation: report from the cystic fibrosis genetic analysis consortium. Am. J. Hum. Genet. 1990, 47:354-359.
65. Shoshani T., Augarten A., Gazit E., et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am. J. Hum. Genet. 1992, 50:222-228.
66. Rozen R., de Braekeleer M., Daigneault J., Ferreira-Rajabi L., Gerdes M., Lamoureux L., et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. Am. J. Med. Genet. 1992, 42:360-364.
67. Zielenski J., Bozon D., Kerem B., Markiewicz D., Durie P., Rommens J.M., et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991, 10:229-235.
68. Welsh M.J., Smith A.E. Molecular mechanisms of CFTR chloride channel dysfunction in CF. Cell 1993, 73:1251-1254.
69. Haardt M., Benharouga M., Lechardeur D., Kartner N., Lukacs G.L. C-terminal truncations destabilize the CF transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J. Biol. Chem. 1999, 274:21873-21877.
70. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000, 67:117-133.
71. Sharma M., Pampinella F., Nemes C., Benharouga M., So J., Du K., et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J. Cell Biol. 2004, 164:923-933.
72. Grove D.E., Rosser M.F., Watkins R.L., Cyr D.M. Analysis of CFTR folding and degradation in transiently transfected cells. Methods Mol. Biol. 2011, 741:219-232.
73. Rowe S.M., Miller S., Sorscher E.J. Cystic fibrosis. N. Engl. J. Med. 2005, 352:1992-2001.
74. De Boeck K., Wilschanski M., Castellani C., Taylor C., Cuppens H., Dodge J., et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006, 61:627-635.
75. Stick S.M., Brennan S., Murray C., Douglas T., von Ungern-Sternberg B.S., Garratt L.W., et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J. Pediatr. 2009, 155:623-628.
76. Linnane B.M., Hall G.L., Nolan G., Brennan S., Stick S.M., Sly P.D., et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am. J. Respir. Crit. Care Med. 2008, 178:1238-1244.
77. Sly P.D., Brennan S., Gangell C., de Klerk N., Murray C., Mott L., et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am. J. Respir. Crit. Care Med. 2009, 180:146-152.
78. Pillarisetti N., Williamson E., Linnane B., Skoric B., Robertson C.F., Robinson P., et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2011, 184:75-81.
79. Lebecque P., Pepermans X., Marchand E., Leonard A., Leal T. ABPA in adulthood: a CFTR-related disorder. Thorax 2011, 66:540-541.
80. Armstrong D.S., Hook S.M., Jamsen K.M., Nixon G.M., Carzino R., Carlin J.B., et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmonol. 2005, 40:500-510.
81. Downey D.G., Bell S.C., Elborn J.S. Neutrophils in cystic fibrosis. Thorax 2009, 64:81-88.
82. Hayes E., Pohl K., McElvaney N.G., Reeves E.P. The cystic fibrosis neutrophil: a specialized yet potentially defective cell. Arch. Immunol. Ther. Exp. (Warsz.) 2011, 59:97-112.
83. Roos D., Griese M., Eickelberg O., Döring G., Mall M.A., Hartl D. CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat. Med. 2010, 16:1018-1023.
84. Jackson P.L., Xu X., Wilson L., Weathington N.M., Clancy J.P., Blalock J.E., et al. Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol. Med. 2010, 16:159-166.
85. Mitola S., Sorbello V., Ponte E., Copreni E., Mascia C., Bardessono M., et al. Tumor necrosis factor-alpha in airway secretions from cystic fibrosis patients upregulate endothelial adhesion molecules and induce airway epithelial cell apoptosis: implications for cystic fibrosis lung disease. Int. J. Immunopathol. Pharmacol. 2008, 21:851-865.
86. Carpagnano G.E., Barnes P.J., Geddes D.M., Hodson M.E., Kharitonov S.A. Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003, 167:1109-1112.
87. Colombo C., Faelli N., Tirelli A.S., Fortunato F., Biffi A., Claut L., et al. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. Int. J. Immunopathol. Pharmacol. 2011, 24:423-432.
88. Gaggar A., Hector A., Bratcher P.E., Mall M.A., Griese M., Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur. Respir. J. 2011, 38:721-727.
89. Thomson E., Brennan S., Senthilmohan R., Gangell C.L., Chapman A.L., Sly P.D., et al. Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis. Free Radic. Biol. Med. 2010, 49:1354-1360.
90. Sorio C., Buffelli M., Angiari C., Ettorre M., Johansson J., Vezzalini M., et al. Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS One 2011, 6:e22212.
91. Legssyer R., Huaux F., Lebacq J., Delos M., Marbaix E., Lebecque P., et al. Azithromycin reduces spontaneous and induced inflammation in deltaf508 cystic fibrosis mice. Respir. Res. 2006, 7:134.
92. Meyer M., Huaux F., Gavilanes X., van den Brûle S., Lebecque P., Lo Re S., et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 2009, 41:590-602.
93. Lebecque P., Leal T., De Boeck C., Jaspers M., Cuppens H., Cassiman J.J. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am. J. Respir. Crit. Care Med. 2002, 165:757-761.
94. Paranjape S.M., Zeitkin P.L. Atypical cystic fibrosis and CFTR related diseases. Clin. Rev. Allergy Immunol. 2008, 35:116-123.
95. Castellani C., Cuppens H., Macek M., Cassiman J.J., Kerem E., Durie P., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J. Cyst. Fibros. 2008, 7:179-196.
96. Rowe S.M., Clancy J.P., Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol. Biol. 2011, 741:69-86.
97. Hug M.J., Derichs N., Bronsveld I., Clancy J.P. Measurement of ion transport function in rectal biopsies. Methods Mol. Biol. 2011, 741:87-107.
98. Cutting G.R. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. N. Y. Acad. Sci. 2010, 1214:57-69.
99. Fisher J.T., Zhang Y., Engelhardt J.F. Comparative biology of cystic fibrosis animal models. Methods Mol. Biol. 2011, 742:311-334.
100. Albelda S.M., Wiewrodt R., Zuckerman J.B. Gene therapy for lung disease: hype or hope?. Ann. Intern. Med. 2000, 132:649-660.
101. Rosenecker J., Huth S., Rudolph C. Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr. Opin. Mol. Ther. 2006, 8:439-445.
102. Griesenbach U., Alton E.W. Current status and future directions of gene and cell therapy for cystic fibrosis. BioDrugs 2011, 25:77-88.
103. Bedwell D.M., Kaenjak A., Benos D.J., Bebok Z., Bubien J.K., Hong J., et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. 1997, 3:1280-1284.
104. Wilschanski M., Famini C., Blau H., Rivlin J., Augarten A., Avital A., et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am. J. Respir. Crit. Care Med. 2000, 161:860-865.
105. Wilschanski M., Yahav Y., Yaacov Y., Blau H., Bentur L., Rivlin J., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 2003, 349:1433-1441.
106. Sermet-Gaudelus I., Renouil M., Fajac A., Bidou L., Parbaille B., Pierrot S., et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 2007, 5:5.
107. Clancy J.P., Bebök Z., Ruiz F., King C., Jones J., Walker L., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2001, 163:1683-1692.
108. Clancy J.P., Rowe S.M., Bebok Z., Aitken M.L., Gibson R., Zeitlin P., et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am. J. Respir. Cell Mol. Biol. 2007, 37:57-66.
109. Kerem E., Hirawat S., Armoni S., Yaakov Y., Shoseyov D., Cohen M., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
110. Sermet-Gaudelus I., Boeck K.D., Casimir G.J., Vermeulen F., Leal T., Mogenet A., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 2010, 182:1262-1272.
111. Rowe S.M., Varga K., Rab A., Bebok Z., Byram K., Li Y., et al. Restoration of W1282X CFTR activity by enhanced expression. Am. J. Respir. Cell Mol. Biol. 2007, 37:347-356.
112. Amaral M.D. CFTR and chaperones: processing and degradation. J. Mol. Neurosci. 2004, 23:41-48.
113. Luciani A., Villella V.R., Esposito S., Brunetti-Pierri N., Medina D., Settembre C., et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell Biol. 2010, 12:863-875.
114. Clancy J.P., Rowe S.M., Accurso F.J., Aitken M.L., Amin R.S., Ashlock M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012, 67:12-18.
115. Dormer R.L., Harris C.M., Clark Z., Pereira M.M., Doull I.J., Norez C., et al. Sildenafil (Viagra) corrects deltaf508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005, 60:55-59.
116. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 1998, 338:1397-1404.
117. Bartolome S.D., Channick R.N. Sildenafil for pulmonary arterial hypertension. Future Cardiol. 2006, 2:137-143.
118. Gavilanes X., Huaux F., Meyer M., Lebecque P., Marbaix E., Lison D., et al. Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice. J. Cyst. Fibros. 2009, 8:203-210.
119. Bonvin E., Le Rouzic P., Bernaudin J.F., Cottart C.H., Vandebrouck C., Crié A., et al. Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice. J. Physiol. 2008, 586:3231-3243.
120. Lubamba B., Lebacq J., Reychler G., Marbaix E., Wallemacq P., Lebecque P., et al. Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur. Respir. J. 2011, 37:72-78.
121. Lubamba B., Lecourt H., Lebacq J., Lebecque P., De Jonge H., Wallemacq P., et al. Preclinical evidence that sildenafil and vardenafil correct cystic fibrosis defects. Am. J. Respir. Crit. Care Med. 2008, 177:506-515.
122. Lubamba B., Lebacq J., Lebecque P., Vanbever R., Leonard A., Wallemacq P., et al. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am. J. Respir. Crit. Care Med. 2009, 179:1022-1028.
123. Coste T.C., Armand M., Lebacq J., Lebecque P., Wallemacq P., Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin. Biochem. 2007, 40:511-520.
124. Coste T.C., Deumer G., Reychler G., Lebecque P., Wallemacq P., Leal T. Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis. Clin. Chem. 2008, 54:388-395.
125. Mimoun M., Coste T.C., Lebacq J., Lebecque P., Wallemacq P., Leal T., et al. Increased arachidonic acid and reduced linoleic acid in F508del cystic fibrosis mice are reversible by GPL-DHA supplementation. J. Nutr. 2009, 139:2358-2364.
126. van Doorninck J.H., French P.J., Verbeek E., Peters R.H.P.C., Morreau H., Bijman J., et al. A mouse model for the cystic fibrosis DF508 mutation. EMBO J. 1995, 14:4403-4411.
127. Colledge W.H., Abelia B.S., Southern K.W., Ratcliff R., Jiang C., Cheng S.H., et al. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat. Genet. 1995, 10:445-452.
128. Zeiher B.G., Eichwald E., Zabner J., Smith J.J., Puga A.P., McCray P.B., et al. A mouse model for the delta F508 allele of cystic fibrosis. J. Clin. Invest. 1995, 96:2051-2064.
129. Leal T., Lebacq J., Vanbinst R., Lederman Ch., De Kock M., Wallemacq P. Successful protocol of anaesthesia for measuring transepithelial nasal potential difference in spontaneously breathing mice. Lab. Anim. UK 2006, 40:43-52.
130. Leal T., Lebacq J., Lebecque P., Cumps J., Wallemacq P. Modified method to measure nasal potential difference. Clin. Chem. Lab. Med. 2003, 41:61-67.
131. Schüller D., Sermet-Gaudeleus I., Wilschanski M., Ballman M., Dechaux M., Edelman A., et al. Basic protocol for transepithelial nasal potential difference (NPD) measurements. J. Cyst. Fibros. 2004, 3:151-155.
132. Leonard A., Lubamba B., Dhooghe B., Noel S., Wallemacq P., Lebecque P., et al. Comparative variability of nasal potential difference measurements in human and mice. Open J Respir Dis 2012, 2:43-56.
133. Leonard A., Dingemanse J., Lebecque P., Leal T. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J. Cyst. Fibros. 2012, 11:231-236.
134. Poschet J.F., Timmins G.S., Taylor-Cousar J.L., Ornatowski W., Fazio J., Perkett E., et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L712-L719.
135. Robert R., Carlile G.W., Pavel C., Liu N., Anjos S.M., Liao J., et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol. Pharmacol. 2008, 73:478-489.
136. Lubamba B., Huaux F., Lebacq J., Marbaix E., Dhooghe B., Panin N., et al. Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice. J. Cyst. Fibros. Apr 11 2012, [Epub ahead of print].
137. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Herebicek M., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355:1481-1485.
138. Cox T.M., Aerts J.M., Andria G., Beck M., Belmatoug N., Bembi B., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 2003, 26:513-526.
139. Elstein D., Hollak C., Aerts J.M.F., van Weely S., Maas M., Cox T.M., et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J. Inherit. Metab. Dis. 2004, 27:757-766.
140. Butters T.D., Dwek R.A., Platt F.M. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 2005, 15:43R-52R.
141. Jacob J.R., Mansfiels K., You J.R., Tennant B.C., Kim Y.H. Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins. J. Microbiol. 2007, 45:431-440.
142. Chapel C., Garcia C., Roingeard P., Zitzmann N., Dubuisson J., Dwek R.A., et al. Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J. Gen. Virol. 2006, 87:861-871.
143. Noël S., Wilke M., Bot A.G., De Jonge H.R., Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J. Pharmacol. Exp. Ther. 2008, 325:1016-1023.
144. Norez C., Noel S., Wilke M., Bijvelds M., Jorna H., Melin P., et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 2006, 580:2081-2086.
145. Norez C., Antigny F., Noel S., Vandebrouck C., Becq F. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am. J. Respir. Cell Mol. Biol. 2009, 41:217-225.
146. Rubinstein R.C., Egan M.E., Zeitlin P.L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing deltaF508-CFTR. J. Clin. Invest. 1997, 100:2457-2465.
147. Sugita M., Kongo H., Shiba Y. Molecular dissection of the butyrate action revealed the involvement of mitogen-activated protein kinase in cystic fibrosis transmembrane conductance regulator biogenesis. Mol. Pharmacol. 2004, 66:1248-1259.
148. Rubinstein R.C., Zeitlin P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med. 1998, 157:484-490.
149. 2-terminal kinase signaling. J. Pharmacol. Exp. Ther. 2008, 326:949-956.
150. Tabary O., Boncoeur E., de Martin R., Peperkok R., Clement A., Scultz C., et al. Calcium-activated regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells. Cell. Signal. 2006, 18:652-660.
151. Wang Y., Loo T.W., Bartlett M.C., Clarke D.M. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J. Biol. Chem. 2007, 282:33247-33251.
152. Pedemonte N., Lukacs G.L., Du K., Caci E., Zegarra-Moran O., Galietta L.J., et al. Small-molecule correctors of defective deltaF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 2005, 115:2564-2571.
153. Loo T.W., Bartlett M.C., Clarke D.M. Rescue of deltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol. Pharm. 2005, 2:407-413.
154. Wang Y., Loo T.W., Bartlett M.C., Clarke D.M. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol. Pharmacol. 2007, 71:751-758.
155. Van Goor F., Straley K.S., Cao D., González J., Hadida S., Hazlewood A., et al. Rescue of deltaf508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L1117-L1130.
156. Dormer R.L., Derand R., McNeilly C.M., Mettey Y., Bulteau-Pignoux L., Metaye T., et al. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci. 2001, 114:4073-4081.
157. Egan M.E., Pearson M., Weiner S.A., Rajendran V., Rubin D., Glöckner-Pagel J., et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304:600-602.
158. Song Y., Sonawane N.D., Salinas D., Qian L., Pedemonte N., Galietta L.J., et al. Evidence against the rescue of defective deltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J. Biol. Chem. 2004, 279:40629-40633.
159. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Cao D., Neuberger T., et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18825-18830.
160. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 2010, 363:1991-2003.
161. Pyle L.C., Ehrhardt A., Mitchell L.H., Fan L., Ren A., Naren A.P., et al. Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 301:L587-L597.
162. Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science 2012, 335:645.
163. Al-Nakkash L., Hu S., Li M., Hwang T.C. A common mechanism for cystic fibrosis conductance regulator protein activation by genistein and benzimidazole analogs. J. Pharmacol. Exp. Ther. 2001, 296:464-472.
164. Dérand R., Bulteau-Pignoux L., Becq F. Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J. Membr. Biol. 2003, 194:109-117.
165. - channel. J. Biol. Chem. 2006, 281:1970-1977.
166. Cai Z., Sheppard D.N. Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity. J. Biol. Chem. 2002, 277:19546-19553.
167. Bertrand J., Boucherle B., Billet A., Melin-Heschel P., Dannhoffer L., Vandebrouck C., et al. Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a. Eur. Respir. J. 2010, 36:311-322.
168. Namkung W., Yao Z., Finkbeiner W.E., Verkman A.S. Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J. 2011, 25:4048-4062.
169. 2+) activated Cl(-) conductance in mouse airways. Biochim. Biophys. Acta 2008, 1783:1993-2000.
170. Suzuki M., Mizuno A. A novel human Cl(-) channel family related to Drosophila flightless locus. J. Biol. Chem. 2004, 279:22461-22468.
171. Suzuki M., Morita T., Iwamoto T. Diversity of Cl(-) channels. Cell. Mol. Life Sci. 2006, 63:12-24.
172. Yang Y.D., Cho H., Koo J.Y., Tak M.H., Cho Y., Shim W.S., et al. TMEM16A confers receptor-activated calcium dependent chloride conductance. Nature 2008, 455:1210-1215.
173. Caputo A., Caci E., Ferrera L., Pedemonte N., Barsanti C., Sondo E., et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008, 322:590-594.
174. Schroeder B.C., Cheng T., Jan Y.N., Jan L.Y. Expression cloning of TMEM16A as calcium-activated chloride channel subunit. Cell 2008, 134:1019-1029.
175. Duran C., Thompson C.H., Xiao Q., Hartzell H.C. Chloride channels: often enigmatic, rarely predictable. Annu. Rev. Physiol. 2010, 72:95-121.
176. Bertrand C.A., Zhang R., Pilewski J.M., Frizzell R.A. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J. Gen. Physiol. 2009, 133:421-438.
177. Ousingsawat J., Schreiber R., Kunzelmann K. Differential contribution of SLC26A9 to Cl(-) conductance in polarized and non-polarized epithelial cells. J. Cell. Physiol. 2012, 227:2323-2329.
178. Avella M., Loriol C., Boulukos K., Borgese F., Ehrenfeld J. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J. Cell. Physiol. 2011, 226:212-223.
179. Knowles M.R., Clarke L.L., Boucher R.C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 1991, 325:533-538.
180. + absorption in wild-type and deltaf508 CFTR-expressing human bronchial epithelia. Am. J. Physiol. 1999, 276:C827-C837.
181. Yerxa B.R., Sabater J.R., Davis C.W., Stutts M.J., Lang-Furr M., Picher M., et al. Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)-(2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther. 2002, 302:871-880.
182. Deterding R.R., Lavange L.M., Engels J.M., Mathews D.W., Coquillette S.J., Brody A.S., et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2007, 176:362-369.
183. Kellerman D., Rossi Mospan A., Engels J., Schaberg A., Gorden J., Smiley L. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to phase 3. Pulm. Pharmacol. Ther. 2008, 21:600-607.
184. Accurso F.J., Moss R.B., Wilmott R.W., Anbar R.D., Schaberg A.E., Durham T.A., et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med. 2011, 183:627-634. TIGER-1 Investigator Study Group.
185. Cloutier M.M., Guernsey L., Mattes P., Koeppen B. Duramycin enhances chloride secretion in airway epithelium. Am. J. Physiol. 1990, 259:C450-C454.
186. Cloutier M.M., Guernsey L., Sha'afi R.I. Duramycin increases intracellular calcium in airway epithelium. Membr. Biochem. 1993, 10:107-118.
187. Oliynyk I., Varelogianni G., Roomans G.M., Johannesson M. Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. APMIS 2010, 118:982-990.
188. Zeitlin P.L., Boyle M.P., Guggino W.B., Molina L. A phase I trial of intranasal Moli 1901 for cystic fibrosis. Chest 2004, 125:143-149.
189. Grasemann H., Stehling F., Brunar H., Widmann R., Laliberte T.W., Molina L., et al. Inhalation of Moli 1901 in patients with cystic fibrosis. Chest 2007, 131:1461-1466.
190. Steiner I., Errhalt P., Kubesch K., Hubner M., Holy M., Bauer M., et al. Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378:323-333.
191. Mohammad-Panah R., Gyomorey K., Rommens J., Choudhury M., Li C., Wang Y., et al. ClC-2 contributes to native chloride secretion by a human intestinal cell line, Caco-2. J. Biol. Chem. 2001, 276:8306-8313.
192. Cuppoletti J., Malinowska D.H., Tewari K.P., Li Q.J., Sherry A.M., Patchen M.L., et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am. J. Physiol. Cell Physiol. 2004, 287:C1173-C1183.
193. Joo N.S., Wine J.J., Cuthbert A.W. Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L811-L824.
194. - secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 2009, 137:976-985.
195. O'Brien C.E., Anderson P.J., Stowe C.D. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study. Ann. Pharmacother. 2011, 45:1061-1066.
196. + transport and improves fluid dynamics in cystic fibrosis airway epithelia. Am. J. Physiol. Cell Physiol. 2005, 289:C512-C520.
197. Vajanaphanich M., Schultz C., Rudolf M.T., Wasserman M., Enyedi P., Craxton A., et al. Long-term uncoupling of chloride secretion from intracellular calcium levels by Ins(3,4,5,6)P4. Nature 1994, 371:711-714.
198. Eckmann L., Rudolf M.T., Ptasznik A., Schultz C., Jiang T., Wolfson N., et al. D-myo-inositol1,4,5,6-tetrakisphosphate produced in human intestinal epithelial cells in response to Salmonella invasion inhibits phosphoinositide 3-kinase signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14456-14460.
199. Irvine R.F., Schell M.J. Back in the water: the return of the inositol phosphates. Nat. Rev. Mol. Cell Biol. 2001, 2:327-338.
200. - current in CFPAC-1 cells. Am. J. Physiol. 1997, 272:C1160-C1168.
201. Carew M.A., Yang X., Schultz C., Shears S.B. myo-Inositol 3,4,5,6-tetrakisphosphate inhibits an apical calcium-activated chloride conductance in polarized monolayers of a cystic fibrosis cell line. J. Biol. Chem. 2000, 275:26906-26913.
202. Traynor-Kaplan A.E., Moody M., Nur M., Gabriel S., Majerus P.W., Drumm M.L., et al. INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia. Am. J. Respir. Cell Mol. Biol. 2010, 42:105-112.